Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References and Further Reading
Afifi AK, Menezes AH, Reed LA, Bell WE. Atypical presentation of X-linked childhood adrenoleukodystrophy with an unusual magnetic resonance imaging pattern. J Child Neurol 1996; 11: 497–499
Asano J-I, Suzuki Y, Yajima S, Iioue K, Shimozawa N, Kondo N, Murase M, Orii T. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev 1994; 16: 454–458
Aubourg P, Dubois-Dalcq M. X-linked adrenoleukodystrophy enigma: how does the ALD peroxisomal transporter mutation affect CNS glia? Glia 2000; 29: 186–190
Aubourg P, Blanche S, Jambaqué I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, Rolland MO, Debré M, Chaussain JL, Griscelli C, Fischer A, Bougnères P-F. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322: 1860–1866
Aubourg P, Adamsbaum C, Lavallard-Rousseau M-C, Rocchiccioli F, Cartier N, Jambaqué I, Jakobezak C, Lemaitre A, Boureau F, Wolf C, Bougnères P-F. A two-year trail of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N Engl J Med 1993; 329: 745–752
Aubourg P, Mandel JL. X-linked adrenoleukodystrophy. Ann NY Acad Sci 1996; 804: 461–476
Barkovich AJ, Ferriero DM, Bass N, Boyer R. Involvement of the pontomedullary corticospinal tracts: a useful finding in the diagnosis of X-linked adrenoleukodystrophy. AJNR Am J Neuroradiol 1997; 18: 95–100
Baumann M, Korenke GC, Widdige-Diedrichs A, Wilichowski E, Hunneman DH, Wilken B, Brockmann K, Klingebiel T, Niethammer D, Kühl J, Ebell W, Hanefeld F. Haematopoietic stem cell transplantation in 12 patients with cerebral Xlinked adrenoleukodystrophy. Eur J Pediatr 2003; 162: 6–14
Bekiesiñska-Figatowska M, Tylki-Szymañska A, Walekci J, Stradomska TJ. MRI findings in a asymptomatic boy with X-linked adrenoleukodystrophy and his symptomatic mother. Neuroradiology 2001; 43: 951–952
Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD, Kass NE, Moser HW. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49: 512–517
Borker A, Yu LC. Unrelated allogeneic bone marrow transplant in adrenoleukodystrophy using CD34+ stem cell selection. Metab Brain Dis 2002; 17: 139–142
Boutin B, Matsuguchi L, Lebon P, Ponsol G, Arthuis C. Immunohistochemical analysis of brain macrophages in adrenoleukodystrophy. Neuropediatrics 1989; 20: 202–206
Brown FR, Chen WW, Kirschner DA, Frayer KL, Powers JM, Moser AB, Moser HW. Myelin membrane from adrenoleukodystrophy brain white matter — biochemical properties. J Neurochem 1983; 41: 341–348
Cartier N, Guidoux S, Rocchiccioli F, Aubourg P. Simvastatin does not normalize very long chain fatty acids in adrenoleukodystrophy mice. FEBS Lett 2000; 478: 205–208
Confort-Gouny S, Vion-Dury J, Chabrol B, Nicoli F, Cozzone PJ. Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Neuroradiology 1995; 37: 568–575
Di Rocco M, Doria-Lamba L, Caruso U. Monozogotic twins with X-linked adrenoleukodystrophy and different phenotypes. Ann Neurol 2001; 50: 424
Dodd A, Rowland SA, Hawkes SLJ, Kennedy MA, Love DR. Mutations in the adrenoleukodystrophy gene. Hum Mutat 1997; 9: 500–511
Domagk J, Linke I, Argyrakis A, Spaar FW, Rahlf G, Schulte FJ. Adrenoleukodystrophy. Neuropediatrics 1975; 6: 41–64
Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci 1999; 22: 4–12
Dumic M, Gubarev n, Sikic N, Roscher A, Plavsic V, Filipovic-Grcic B. Sparse hair and multiple endocrine disorders in two women heterozygous for adrenoleukodystrophy. Am J Med Genet 1992; 43: 829–832
Dunne E, Hyman NM, Huson SM, Németh AH. A novel point mutation in X-linked adrenoleukodystrophy presenting as spinocerebellar degeneration. Ann Neurol 1999; 45: 652–655
Dziewas R, Stögbauer F, Oelerich M, Ritter M, Husstedt IW. A case of adrenomyeloneuropathy with unusual lesion pattern in magnetic resonance imaging. J Neurol 2001; 248: 341–342
Edwin D, Speedie LJ, Kohler W, Naidu S, Kruse B, Moser HW. Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. Ann Neurol 1996; 40: 675–678
Eichler FS, Barker PB, Cox C, Edwin D, Ulug AM, Moser HW, Raymond GV. Proton MR spectroscopic imaging predicts lesion progression or MRI in X-linked adrenoleukodystrophy. Neurology 2002; 58: 901–907
Eichler FS, Itoh R, Barker PB, Mori S, Garrett ES, van Zijl PCM, Moser HW, Raymond GV, Melhem ER. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience. Radiology 2002; 225: 245–252
Elrington GM, Bateman DE, Jeffrey MJ, Flawton N. Adrenoleukodystrophy: heterogeneity in two brothers. J Neurol Neurosurg Psychiatry 1989; 52: 310–313
Engelbrecht V, Rassek M, Gärtner J, Kahn T, Mödder U. The value of new MRI techniques in adrenoleukodystrophy. Pediatr Radiol 1997; 27: 207–215
Farrell DF, Hamilton SR, Knauss TA, Sanocki E, Deeb SS. X-Linked adrenoleukodystrophy: adult cerebral variant. Neurology 1993; 43: 1518–1522
Fatemi A, Barker PB, Uluğ AM, Nagae-Poetcher LM, Beauchamp NJ, Moser AB, Raymond GV, Moser HW, Naidu S. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy. Neurology 2003; 60: 1301–1307
Feigenbaum V, Gélot A, Casanova P, Daumas-Duport C, Aubourg P, Dubouis-Dalcq M. Apoptosis in the central nervous system of cerebral adrenoleukodystrophy patients. Neurobiol Dis 2000; 7: 600–612
Gärtner J, Braun A, Holzinger A, Roerig P, Lenard H-G, Roscher AA. Clinical and genetic aspects of X-linked adrenoleukodystrophy. Neuropediatrics 1998; 29: 3–13
Garg BP, Markand ON, DeMeyer WE, Warren C Jr. Evoked response studies in patients with adrenoleukodystrophy and heterozygous relatives. Arch Neurol 1983; 40: 356–359
Garside S, Rosebush PI, Levinson AJ, Mazurek MF. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. J Clin Psychiatry 1999; 60: 460–468
Hershkovitz E, Narkis G, Shorer Z, Moser AB, Watkins PA, Moser HW, Manor E. Cerebral X-linked adrenoleukodystrophy in a girl with Xq27-Ter deletion. Ann Neurol 2002; 52: 234–237
Hitomi T, Mezaki T, Tsujii T, Kinoshita M, Tomimoto H, Ikeda A, Shimohama S, Okazaki T, Uchiyama T, Shibasaki H. Improvement of central motor conduction after bone marrow transplantation in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 2003; 74: 373–375
Hong-Magno ET, Muraki AS, Huttenlocher PR. Atypical CT scans in adrenoleukodystrophy. J Comput Assist Tomogr 1987; 11: 333–336
Igarashi M, Schaumburg HH, Powers J, Kishimoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976; 26: 851–860
Ito M, Blumberg BM, Mock DJ, Goodman AD, Moser AB, Moser HW, Smith KD, Powers JM. Potential environmental and host participants in the early white matter lesions of adrenoleukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD-1 mediated lipid antigen presentation. J Neuropathol Exp Neurol 2001; 60: 1004–1019
Ito R, Melhem ER, Mori S, Eichler FS, Raymond GV, Moser HW. Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurology 2001; 56: 544–547
Jensen ME, Sawyer RW, Braun IF, Rizzo WB. MR imaging appearance of childhood adrenoleukodystrophy with auditory, visual, and motor pathway involvement. Radiographics 1990; 10: 53–66
Izquierdo M, Adamsbaum C, Benosman A, Aubourg P, Bittoun J. MR spectroscopic imaging of normal-appearing white matter in adrenoleukodystrophy. Pediatr Radiol 2000; 30: 621–629
Jorge P, Quelhas D, Oliveira P, Pinto R, Nogueira A. X-Linked adrenoleukodystrophy in patients with idiopathic Addison disease. Eur J Pediatr 1994; 153: 594–597
Kano S, Watanabe M, Kanai M, Koike R, Onodera O, Tsuji S, Okamoto K, Shoji M. A Japanese family with adrenoleukodystrophy with a codon 291 deletion: a clinical, biochemical, pathological, and genetic report. J Neurol Sci 1998; 158: 187–192
Kaplan PW, Tusa RJ, Shankroff J, Heller J, Moser HW. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol 1993; 34: 169–174
Kemp S, Mooyer PAW, Bolhuis PA, van Geel BM, Mandel JL, Barth PG, Aubourg P, Wanders RJA. ALDP Expression in fibroblasts of patients with X-linked adrenoleukodystrophy. J Inherit Metab Dis 1996; 19: 667–674
Kemp S, Wei H-M, Lu J-F, Braiterman LT, McGuinness MC, Moser AB, Watkins PA, Smith KD. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 1998; 4: 1261–1268
Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, Cutting GR, Wanders RJA, Moser HW. ABCD1 Mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 2001; 18: 499–515
Koike R, Tsuji S, Ohno T, Suzuki Y, Orii T, Miyatake T. Physiological significance of fatty acid elongation system in adrenoleukodystrophy. J Neurol Sci 1991; 103: 188–194
Kok F, Neumann S, Sarde C-O, Zheng S, Wu K-H, Wei H-M, Bergin J, Watkins PA, Gould S, Sack G, Moser H, Mandel J-L, Smith KD. Mutational analysis of patients with X-linked adrenoleukodystrophy. Hum Mutat 1995; 6: 104–115
Korenke GC, Christen H-J, Kruse B, Hunneman DH, Hanefeld F. Progression of X-linked adrenoleukodystrophy under interferon-β therapy. J Inherit Metab Dis 1997; 20: 59–66
Kukowski B. Magnetic transcranial brain stimulation and multimodality evoked potentials in an adrenoleukodystrophy patient and members of his family. Electroencephalogr Clin Neurophysiol 1991; 78: 260–262
Kumar AJ, Rosenbaum AE, Naidu S, Wener L, Citrin CM, Lindenberg R, Kim WS, Zinreich SJ, Molliver ME, Mayberg HS, Moser HW. Adrenoleukodystrophy: correlating MR imaging with CT. Radiology 1987; 165: 497–504
Kumar AJ, Köhler W, Kruse B, Naidu S, Bergin A, Edwin D, Moser HW. MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol 1995; 16: 1227–1237
Kurihara M, Kumagai K, Yagishita S, Imai M, Watanabe M, Suzuki Y, Orii T. Adrenoleukomyeloneuropathy presenting as cerebellar ataxia in a young child: a probable variant of adrenoleukodystrophy. Brain Dev 1993; 15: 377–380
Kurihara M, Kumagai K, Noda Y, Yagishita S. An autopsy case of atypical adrenoleukomyeloneuropathy in childhood. Brain Dev 2000; 22: 394–397
Kusaka H, Imai T. Ataxic variant of adrenoleukodystrophy: MRI and CT findings. J Neurol 1992; 239: 307–310
Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, Lockman L, Latchaw RE, Krivit W. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994; 15: 1761–1766
Loes DJ, Stillman AE, Hite S, Shapiro E, Lockman L, Latchaw RE, Moser H, Krivit W. Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. AJNR Am J Neuroradiol 1994; 15: 1767–1771
Loes DJ, Fatemi A, Melhem ER, Gupte N, Bezman L, Moser HW, Raymond GV. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003; 61: 369–374
Maier EM, Kammerer S, Muntau AC, Wichers M, Braun A, Roscher AA. Symptoms in carriers of adrenoleukodystrophy relate to skewed X Inactivation. Ann Neurol 2002; 52: 683–688
Maris T, Androulidakis EJ, Tzagournissakis M, Papavassiliou S, Moser H, Plaitakis A. X-linked adrenoleukodystrophy presenting as neurologically pure familial spastic paraparesis. Neurology 1994; 45: 1101–1104
Marsh WW, Hurst DL. Variable phenotypes in a family kindred with adrenoleukodystrophy. Pediatr Neurol 1991; 7: 50–52
Martin JJ, Ceuterick C, Libert J. Skin and conjunctival nerve biopsies in adrenoleukodystrophy and its variants. Ann Neurol 1980; 8: 291–295
McGuinness MC, Lu J-F, Zhang H-P, Dong G-X, Heinzer AK, Watkins PA, Powers J, Smith KD. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol Cell Biol 2003; 23: 744–753
Melhem ER, Breitner SN, Ulug AM, Raymond GV, Moser HW. Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging. AJR Am J Roentgenol 1996; 166: 689–695
Melhem ER, Loes DJ, Georgiades CG, Raymond GV, Moser HW. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol 2000; 21: 839–844
Melhem ER, Gotwald TF, Itho R, Zinreich SJ, Moser HW. T2 relaxation measurements in X-linked adrenoleukodystrophy performed using dual-echo fast fluid-attenuated inversion recovery MR imaging. AJNR Am J Neuroradiol 2001; 22: 733–776
Mo YH, Chen YF, Liu HM. Adrenomyeloneuropathy, a dynamic disorder: brain magnetic resonance imaging of two cases. Neuroradiology 2004; 46: 296–300
Molzer B, Bernheimer H, Budka H, Pilz P, Toifl K. Accumulation of very long chain fatty acids is common to 3 variants of adrenoleukodystrophy (ALD). J Neurol Sci 1981; 51: 301–310
Moser H, Dubey P, Fatemi A. Progress in X-linked adrenoleukodystrophy. Curr Opin Neurol 2004; 17: 263–269
Moser HW. Adrenoleukodystrophy: natural history treatment and outcome. J Inherit Metab Dis 1995; 18: 435–447
Moser HW. Adrenoleukodystrophy. Curr Opin Neurol 1995; 8: 221–226
Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997; 120: 1485–1508
Moser HW, Moser AB, Frayer KK, Chen W, Schulman JD, O’Neill BP, Kishimoto Y. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981; 31: 1241–1249
Moser HW, Moser AB, Naidu S, Bergin A. Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991; 13: 254–261
Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, Stine OC, Merette C, Ott J, Krivit W, Shapiro E. Adrenoleukodystrophy: Phenotypic variability and implications for therapy. J Inherit Metab Dis 1992; 15: 645–664
Moser HW, Loes DJ, Melhem ER, Raymond GV, Bezman L, Cox CS, Lu S-e. X-linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000; 31: 227–239
Moser HW, Brezman L, Lu SE, Raymond GV. Therapy of X-linked adrenoleukodystrophy: prognosis based upon age and MRI abnormality and plans for placebo-controlled trails. J Inherit Metab Dis 2000; 23: 273–277
Moser HW, Raymond GV, Koehler W, Sokolowski P, Hanefeld F, Korenke GC, Green A, Loes DJ, Hunneman DH, Jones RO, Lu SE, Uziel G, Giros ML, Roels F. Evaluation of the preventive effect of glyceryl trioleate-trierucate (“Lorenzo’s oil”) therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. Adv Exp Med Biol 2003; 544: 369–387
Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, Poustka AM, Mandel JL, Aubourg P. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361: 726–730
Nishio H, Kodama S, Tsubota T, Takumi T, Takahashi T, Yokoyama S, Matsuo T. Adrenoleukodystrophy without adrenal insufficiency and its magnetic resonance imaging. J Neurol 1985; 232: 265–270
Nowaczyk MJM, Saunders EF, Tein I, Blaser SI, Clarke JTR. Immunoablation does not delay the neurologic progression of X-linked adrenoleukodystrophy. J Pediatr 1997; 131: 453–455
O’Neill BP, Marmion LC, Feringa ER. The adrenoleukomyeloneuropathy complex: expression in four generations. Neurology 1981; 31: 151–156
O’Neill BP, Moser HW, Saxena KM. Familial X-linked Addison disease as an expression of adrenoleukodystrophy (ALD): elevated C26 fatty acid in cultured skin fibroblasts. Neurology 1982; 32: 543–547
O’Neill GN, Aoki M, Brown RH Jr. ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN. Neurology 2001; 57: 1956–1962
Pai GS, Khan M, Barbosa E, Key L, Craver JR, Curé JK, Betros R, Singh I. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 2000; 69: 312–322
Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, Singh I. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 2003; 14: 425–439
Pasco A, Kalifa G, Sarrazin JL, Adamsbaum C, Aubourg P. Contribution of MRI to the diagnosis of cerebral lesions of adrenoleukodystrophy. Pediatr Radiol 1991; 21: 161–163
Philips JP, Lockman LA, Shapiro EG, Blazar BR, Loes DJ, Moser HW, Krivit W. CSF findings in adrenoleukodystrophy: correlation between measures of cytokines, IgG production, and disease severity. Pediatr Neurol 1994; 10: 289–294
Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo’s oil. Ann Neurol 1994; 36: 741–746
Powell H, Tindall R, Schultz P, Paa D, O’Brien J, Lampert P. Adrenoleukodystrophy. Electron microscopic findings. Arch Neurol 1975; 32: 250–260
Powers JM, Moser HG. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol 1998; 8: 101–120
Powers JM, Schaumburg HH. Adreno-leukodystrophy (sexlinked Schilder’s disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am J Pathol 1974; 76: 481–491
Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51: 630–643
Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000; 59: 89–102
Powers JM, DeCiero DP, Cox C, Richfield EK, Ito M, Moser AB, Moser HW. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 2001; 60: 493–501
Rajanayagam V, Balthazor M, Shapiro EG, Krivit W, Lockman L, Stillman AE. Proton MR spectroscopy and neuropsychological testing in adrenoleukodystrophy. AJNR Am J Neuroradiol 1997; 18: 1909–1914
Ramsey RB, Banik NL, Scott T, Davison AN. Neurochemical findings in adreno-leukodystrophy. J Neurol Sci 1976; 29: 277–294
Ravid S, Diamond AS, Eviatar L. Coma as an acute presentation of adrenoleukodystrophy. Pediatr Neurol 2000; 22: 237–239
Restuccia D, Di Lazzaro V, Valeriani M, Oliviero A, Le Pera D, Colosimo C, Brudi N, Cappa M, Bertini E, Di Biase A, Tonali P. Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Brain 1997; 120: 1139–1148
Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft BS, Jensen ME, Jennings SS, Davis S, Jaitly R, Sgro JA. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989; 39: 1415–1422
Ronghe MD, Barton J, Jardine PE, Crowne EC, Webster MH, Armitage M, Allen JT, Steward CG. The importance of testing for adrenoleukodystrophy in males with idiopathic Addison’s disease. Arch Dis Child 2002; 86: 185–189
Samadja D, Cabre Ph, Kujas M, Vernant J-C, Rivierez M. Intracranial hypertension as an unusual presentation of adrenoleukodystrophy. Eur J Neurol 1997; 4: 413–415
Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol 1975; 32: 577–591
Schaumburg HH, Powers JM, Raine CS, Spencer PS, Griffin JW, Prineas JW, Boehme DM. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. General pathologic, neuropathologic, and biochemical aspects. Neurology 1977; 27: 1114–1119
Scholte W, Molzer B, Peiffer J, Poremba M, Schumm F, Harzer K, Schnabel R, Bernheimer H. Adrenoleukodystrophy in an adult female. A clinical, morphological and neurochemical study. J Neurol 1987; 235: 1–9
Schmidt S, Träber F, Block W, Keller E, Pohl C, von Oertzen J, Schild H, Schlegel U, Klockgether T. Phenotype assignment in symptomatic female carriers of X-linked adrenoleukodystrophy. J Neurol 2001; 248: 36–44
Schneider JFL, Il’yasov KA, Boltshauser E, Hennig J, Martin E. Diffusion tensor imaging in cases of adrenoleukodystrophy: preliminary experience as a marker for early demyelination? AJNR Am J Neuroradiol 2003; 24: 819–824
Schöder JM, Mayer M, Weis J. Mitochondrial abnormalities and intrafamilial variability of sural nerve biopsy findings in adrenomyeloneuropathy. Acta Neuropathol (Berl) 1996; 92: 64–69
Shapiro E, Krivit W, Lockman L, Jambaqué, Peters C, Cowan M, Harris R, Blanche S, Bordigoni P, Loes D, Ziegler R, Crittenden M, Ris D, Berg B, Cox C, Moser H, Fisher A, Aubourg P. Longterm effect of bone-marrow transplantation for childhoodonset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356: 713–718
Singh I, Khan M, Key L, Pai S. Lovastatin for x-linked adrenoleukodystrophy. N Engl J Med 1998; 339: 702–703
Smith KD, Kemp S, Braiterman LT, Lu J-F, Wei H-M, Geraghty M, Stetten G, Bergin JS, Pevsner J, Watkins PA. X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res 1999; 24: 521–535
Snyder RD, King JN, Keck GM, Orrison WW. MR imaging of the spinal cord in 23 subjects with ALD-AMN complex. AJNR Am J Neuroradiol 1991; 12: 1095–1098
Sobue G, Ueno-Natsukari IU, Okamoto H, Connell TA, Aizawa I, Mizoguchi K, Honma M, Ishakawa G, Mitusma T, Natsukari N. Phenotypic heterogeneity of an adult form of adrenoleukodystrophy in monozygotic twins. Ann Neurol 1994; 36: 912–915
Steinberg SJ, Kemp S, Braiterman LT, Watkins PA. Role of verylong-chain-acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. Ann Neurol 1999; 46: 409–412
Stephenson DJ, Bezman L, Raymond GV. Acute presentation of childhood adrenoleukodystrophy. Neuropediatrics 2000; 31: 293–297
Tan E-K, Lim S-H, Chan L-L, Wong M-C, Tan K-P. X-linked adrenoleukodystrophy: spinocerebellar variant. Clin Neurol Neurosurg 1999; 101: 137–140
Tanaka K, Koyama A, Koike R, Ohno T, Atsumi T, Miyatake T. Adrenomyeloneuropathy: report of a family and electron microscopical findings in peripheral nerve. J Neurol 1985; 232: 73–78
Terakawa H, Yanagihara T, Abe K. Unusual lateralization of adrenoleukodystrophy lesions on neuroimaging. J Neuroimaging 1997; 7: 121–123
Theda C, Moser AB, Powers JM, Moser HW. Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci 1992; 110: 195–204
Uchiyama M, Hata Y, Tada S. MR imaging of adrenoleukodystrophy. Neuroradiology 1991; 33: 25–29
Uyama E, Iwagoe H, Maeda J, Nakamura M, Terasaki T, Ando M. Presenile-onset cerebral adrenoleukodystrophy presenting as Balint’s syndrome and dementia. Neurology 1993; 43: 1249–1251
Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991; 13: 274–279
van der Knaap MS, Valk J. MR of adrenoleukodystrophy: histopathologic correlations. AJNR Am J Neuroradiol 1989; 10: S12–S14
van Geel BM, Assies J, Weverling GJ, Barth PG. Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in the Netherlands: a survey of 30 kindreds. Neurology 1994; 44: 2343–2346
van Geel BM, Assies J, Wanders RJA, Barth PG. X-linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry 1997; 63: 4–14
van Geel BM, Assies J, Haverkort EB, Koelman JHTM, Verbeeten B Jr, Wanders RJA, Barth PG. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil.” J Neurol Neurosurg Psychiatry 1999; 67: 290–299
van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol. 2001; 49: 186–194
Verrips A, Willemsen MAAP, Rubio-Gozalbo E, de Jong J, Smeitink JAM. Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy. Ann Neurol 2000; 47: 552–553
Wanders RJA, van Roermund CWT, Lageweg W, Jakobs BS, Schutgens RBH, Nijenhuis AA, Tager JM. X-Linked adrenoleukodystrophy: biochemical diagnosis and enzyme defect. J Inherit Metab Dis 1992; 15: 634–644
Wanders RJA, Mooyer PW, Dekker C, Vreken P. X-Linked adrenoleukodystrophy: improved prenatal diagnosis using both biochemical and immunological methods. J Inherit Metab Dis 1998; 21: 285–287
Waragai M, Takaya Y, Hayashi M, Shibata N, Kobayashi M. MRI of adrenoleukodystrophy involving predominantly the cerebellum and brain stem. Neuroradiology 1996; 38: 788–791
Watkins PA, Gould JS, Smith MA, Braiterman LT, Wei H-M, Kok F, Moser AB, Moser HW, Smith KD. Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet 1995; 57: 292–301
Weinhofer I, Forss-Petter S, ZŽigman M, Berger J. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 2002; 11: 2701–2708
Weller M, Liedtke W, Petersen D, Opitz H, Poremba M. Very-lateonset adrenoleukodystrophy: possible precipitation of demyelination by cerebral contusion. Neurology 1992; 42: 367–370
Wilken B, Dechent P, Brockmann K, Finsterbusch J, Baumann M, Ebell W, Korenke GC, Pouwels PJW, Hanefeld FA, Frahm J. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatric 2003; 34: 237–246
Wilson R, Sargent JR. Lipid and fatty acid composition of brain tissue from adrenoleukodystrophy patients. J Neurochem 1993; 61: 290–297
Zammarchi EM, Donati MA, Tucci F, Fonda C, Fanelli F, Pazzaglia R. Acute onset of X-linked adrenoleukodystrophy mimicking encephalitis. Brain Dev 1994; 16: 238–240
Zhang LX, Baski R, Fine E, Moser HW. Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment. J Neurol Neurosurg Psychiatry 2002; 74: 822–823
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2005). X-Linked Adrenoleukodystrophy. In: Magnetic Resonance of Myelination and Myelin Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27660-2_21
Download citation
DOI: https://doi.org/10.1007/3-540-27660-2_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22286-6
Online ISBN: 978-3-540-27660-9
eBook Packages: MedicineMedicine (R0)